Last reviewed · How we verify
QLS5132; Bevacizumab
At a glance
| Generic name | QLS5132; Bevacizumab |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- QLS5132 Combination Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLS5132; Bevacizumab CI brief — competitive landscape report
- QLS5132; Bevacizumab updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI